Quadrosilan, formerly known as Cisobitan and KABI-1774, is a synthetic, nonsteroidal estrogen that was developed in the 1970s and that is or has been used as an antigonadotropic agent in the treatment of prostate cancer. It is an organosilicon compound, and is formerly known as 2,6-cisdiphenylhexamethylcyclotetrasiloxane. Quadrosilan has estrogenic activity equivalent to that of estradiol, and can produce feminization and gynecomastia as side effects in male patients. References: Alfthan O, Andersson L, Esposti PL, Fossa SD, Gammelgaard PA, Gjores JE, Isacson S, Rasmussen F, Ruutu M, von Schreeb T, Setterberg G, Strandell P, Strindberg B. Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study. Scand J Urol Nephrol. 1983;17(1):37-43. PubMed PMID: 6346476.

纯度：≥98%

CAS：4657-20-9